CD4^+^IL-10^+^ T Cells -- A Heterogeneous Population of Cells with a Suppressive Function {#S1}
=========================================================================================

In 1997, Groux et al. described a unique population of CD4^+^ T lymphocytes generated after *in vitro* stimulation of CD4^+^ T cells from the T cell receptor (TCR) transgenic DO11-10 mouse with ovalbumin peptide (OVA) and IL-10 or with IL-10 alone. These OVA-specific CD4^+^ T cells produced high levels of IL-10 and IL-5, moderate levels of IFNγ and TGFβ, low levels of IL-2 and IL-4, and proliferated poorly in response to peptide stimulation ([@B1]). High levels of IL-10 suggested a regulatory potential for these cells, since IL-10 is crucial for limiting proinflammatory and autoimmune responses \[reviewed in Ref. ([@B2], [@B3])\]. IL-10-deficient mice develop severe colitis, accompanied by tissue damage and excessive inflammation ([@B4]). Analysis of this model as well as further studies demonstrated that IL-10 is able to block immune responses at different levels by acting directly and indirectly on both innate and adaptive arms of the immune system \[reviewed in Ref. ([@B5])\]. As a result, IL-10 can inhibit production of proinflammatory cytokines, antigen presentation, and cell proliferation.

In the original paper, the reconstitution of *SCID* mice with naive CD4^+^ T cells and OVA-specific CD4^+^IL-10^+^ T cell clones resulted in prevention of colitis ([@B1]). Later on, several other groups confirmed the antigen-specific suppressive potential of CD4^+^IL-10^+^ T cells *in vivo* using colitis ([@B4]), experimental autoimmune encephalomyelitis (EAE) ([@B6]--[@B10]), collagen-induced arthritis ([@B11]), and allergy ([@B12]) disease models. Our laboratory has developed an animal model of multiple sclerosis (MS) using a TCR transgenic system. More than 90% of CD4^+^ T cells in transgenic Tg4 mice express a Vβ8.2 TCR specific for the myelin basic protein (MBP) peptide Ac1--9 presented in the context of MHC I-A^u^ ([@B13]). This allowed us to conduct detailed phenotypic analysis of antigen-specific CD4^+^IL-10^+^ T cells and identify panel of inhibitory receptors (IRs), which could serve as markers for these cells ([@B7]), (see [The Need to Discover a Surrogate Marker for Regulatory Tr1-Like T Cells](#S2){ref-type="sec"}).

CD4^+^IL-10^+^ T cells can also be generated using human peripheral blood mononuclear cells (PBMC) after stimulation with allogeneic monocytes in the presence of IL-10 ([@B1]). They produce high levels of IL-10 and low levels of IL-2 and IL-4, after re-stimulation with αCD3 and αCD28 antibodies, and similar to the murine CD4^+^IL-10^+^ T cells can suppress responder CD4^+^ T cells *in vitro* ([@B14]--[@B17]). These results were obtained using several different protocols for the generation of the CD4^+^IL-10^+^ T cell population. They involved stimulation with a specific subset of antigen-presenting cells, including plasmacytoid dendritic cells (DCs), immature DCs, or tolerogenic DC ([@B1], [@B18]--[@B20]); the presence of cytokines, including IL-10, IL-6, IL-21, or IL-27 ([@B21]--[@B24]); or using antibodies against various costimulatory molecules, such as CD46, CD2, and CD55 ([@B25], [@B26]), as well as vitamin D3 and immunosuppressive drugs ([@B27]). Different laboratories adopted a different set of stimuli, which in their experimental setup worked most efficiently to generate high numbers of CD4^+^IL-10^+^ T cells. However, one could question the physiological relevance of such manipulations, because they cannot re-create a complex *in vivo* environment. Also, different protocols result in the emergence of various subpopulations of CD4^+^IL-10^+^ T cells, making characterization of these cells and discovery of specific marker/s of the CD4^+^IL-10^+^ T cell population even more challenging. Despite the heterogeneity of the described human CD4^+^IL-10^+^ populations, these are generally referred to as T regulatory type 1 cells (Tr1). Nevertheless, it is worth noting that to date, it has not been proven that they represent a unique cell lineage; therefore, we will refer them here as *Tr1-like T cells*.

The Need to Discover a Surrogate Marker for Regulatory Tr1-Like T Cells {#S2}
=======================================================================

The existence of antigen-specific suppressor Tr1-like T cells makes them an appealing target for designing antigen-specific therapies to treat a wide array of autoimmune diseases and to avoid unnecessary and often burdensome side effects associated with conventional immunosuppressive therapies ([@B28]). A constitutively expressed surface marker for Tr1-like T cells would allow us to monitor the emergence, numbers, and functionality of these cells. Many groups have tried to identify such a marker in mouse and man ([@B16], [@B29]--[@B32]). In 2013, Gagliani et al. postulated that lymphocyte-activation protein 3 (LAG-3) and CD49b are markers for human Tr1-like T cells ([@B17]). LAG-3 belongs to a large family of IRs that are upregulated on activated T cells ([@B33]). Here, we discuss the significance of the published findings in the context of other relevant IRs.

The *in vivo* data from our laboratory ([@B7]) demonstrated that administration of soluble MBP Ac1--9 peptide, using a dose escalation protocol, resulted in abrogation of EAE, which coincided with appearance of antigen-specific CD4^+^IL-10^+^ T cells. A majority of these cells expressed T cell immunoglobulin and mucin domain-3 (TIM-3), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and 50% of the cells were CD49b^+^, which is in sharp contrast with the expression pattern observed on the IL-10^−^ T cell subset, where all three markers were present in 6--9% of the cells. Programed cell death protein 1 (PD-1) and LAG-3 were found in the majority of CD4^+^ T cells, regardless of IL-10 production. These IRs are involved in several mechanisms regulating T cell signaling \[reviewed in Ref. ([@B33], [@B34])\]. PD-1 and TIM-3 bind intracellular mediators as SHIP-1/2 (PD-1), Fyn, and PI3K kinase (TIM-3) to deactivate the downstream signaling molecules, and PD-1 can also induce inhibitory genes that inhibit T cell function. TIGIT and LAG-3 prevent optimal signal transduction at the cell membrane by sequestering counter receptors/ligands together with preventing proper formation of the immunological synapse \[reviewed in Ref. ([@B33], [@B34])\]. Importantly, these events are dysregulated not only during autoimmune responses ([@B35]--[@B37]) but also in tumor formation. PD-1, TIM-3, and LAG-3 are found in T cells isolated from melanoma patients ([@B38]--[@B40]); therefore, their expression on T cells is also relevant for the development of new anticancer therapies.

PD-1, belonging to the CD28/CTLA-4 family, provides a negative signal following antigen stimulation \[reviewed in Ref. ([@B41])\]. Depending on the genetic background, PD-1^−/−^ mice develop a range of autoimmune disorders: lupus-like glomerulonephritis in the C57BL/6 strain, autoimmune dilated cardiomyopathy and gastritis in BALB/C, acute type 1 diabetes mellitus (T1DM) in NOD ([@B42]), and myocarditis in MRL, suggesting that other genetic, inherent factors act synergistically with PD-1 in each mouse strain ([@B36]). Clearly, PD-1 plays an important role in the maintenance of peripheral tolerance, but due to abundant expression on activated T cells, it is unlikely to be a biomarker for Tr1-like T cells.

Apart from PD-1, deficiency in any other of the above-mentioned IRs does not result in the spontaneous development of autoimmune disorders. NOD LAG-3-deficient mice show mild enhancement of T lymphocyte responses, unless crossed with PD-1^−/−^ knockout mice, which causes a lethal myocarditis ([@B36]). TIGIT^−/−^ mice are more susceptible to EAE and show only augmented T cell responses when challenged with MOG peptide *in vivo* ([@B37]). CD49b deficiency leads to failure of the establishment of memory T cells in the bone marrow ([@B43]), but it does not have any profound effect on peripheral tolerance, while TIM-3^−/−^ mice and mice treated with a TIM-3 Ig fusion protein exhibit moderate defects in induction of antigen-specific tolerance \[reviewed in Ref. ([@B44])\].

Regarding surface expression, most of the above-mentioned IRs are found in cells with regulatory properties. TIGIT is expressed on human Tr1-like T cells (our observation) but also on human T~reg~ Foxp3^+^ cells ([@B45]). Furthermore, its presence at the cell surface coincides with increased expression of ICOS, TIM-3, and PD-1 on murine T~reg~ cells ([@B37]). TIM-3 is upregulated upon activation *in vitro* in the human T~reg~ subset ([@B46]). Recently, it has also been reported that murine CD4^+^CD49b^+^ T cells produce high levels of IL-10 and are potent suppressors of arthritis severity when injected *in vivo* ([@B47]).

To gain a more detailed understanding of how the expression of PD-1, LAG-3, TIM-3, TIGIT, and ICOS correlates with IL-10 production by human CD4^+^ T cells, we developed a protocol to generate IL-10^+^ CD4^+^ T cells after a different length of stimulation *in vitro*. The first approach involved isolation of memory and naive T cells and stimulating them with αCD3 and αCD28 antibodies in presence or absence of IL-27, known stimuli for Tr1-like T cell generation ([@B21], [@B22]). IL-27 boosted the percentages of CD4^+^IL-10^+^ T cells from 10 to 18% on day 3, which on day 7 decreased to 14% in the presence of IL-27 and 5% in its absence (Figure [1](#F1){ref-type="fig"}A). However, adding IL-27 did not alter the surface phenotype of Tr1-like T cells (data not shown). Initially, the induction of IL-10 production was accompanied by a slight increase in proportions of cells expressing CD49b and TIM-3 within the IL-10^+^ T cell subset, but this was not statistically significant. By day 7, CD49b was found in similar percentages on both IL-10^+^ and IL-10^−^ T cells (Figure [1](#F1){ref-type="fig"}B). CD49b and TIM-3 were co-expressed by the IL-10^+^ T cell fraction, but on day 7, CD49b^+^ cells were mainly TIM-3^−^. LAG-3 was expressed by 8.6% of IL-10^+^ T cells on day 7 (Figure [1](#F1){ref-type="fig"}B), and among these cells, 30% co-expressed TIM-3. The co-expression of LAG-3 and CD49b was observed only on a small proportion of IL-10^+^ subset (Figure [1](#F1){ref-type="fig"}B, right panel). The proportion of cells expressing TIGIT was similar between IL-10^+^ and IL-10^−^ subsets of CD4^+^ T cells (Figure [1](#F1){ref-type="fig"}B), and approximately half of them co-expressed TIM-3. Our observations led us to conclude that none of the tested IRs are exclusively expressed on IL-10-producing T cells, and their expression is dynamic, changing over the time course of cell culture.

![**(A)** Naive and memory CD4^+^ T cells were isolated from PBMC from healthy donors by magnetic selection and stimulated with plate-bound 1 μg/ml αCD3 and 2 μg/ml αCD28 ± 100 ng/ml of IL-27. Intracellular staining for IL-10 was performed on days 3 and 7 after an additional 4-h stimulation with PMA/ionomycin in the presence of Golgi stop. Graphs show the percentages (mean value ± SEM, *n* = 3 donors) of viable CD4^+^IL-10^+^ T cells derived from the naive or memory cell subsets (left panel). A representative dot plot of CD4 and IL-10 staining on memory-derived CD4^+^ T cells on day 7 is shown in the right panel. **(B)** Expression of inhibitory receptors (IRs) on CD4^+^IL-10^+/−^ T cells derived from memory pool after 7 days of cell culture in the presence of 1 μg/ml αCD3 and 2 μg/ml αCD28 examined by flow cytometry. The black bars represent the average percentage of IL-10^+^ and white bars the IL-10^−^ cell fractions, respectively (mean + SEM, *n* = 3 donors). Right panel shows a representative dot plot of CD49b and LAG-3 expression on day 7 by memory CD4^+^IL-10^+/−^ stimulated with αCD3 and αCD28 ± IL-27.](fimmu-07-00355-g001){#F1}

These results were very different from the data generated *in vivo* in the tolerance model ([@B7]). Therefore, we used a modified version of the protocol previously developed in our laboratory ([@B48]), which involved the *ex vivo* isolation of IL-10^+^ CD4^+^ T cells, a short stimulation of unfractionated CD4^+^ T cells with αCD3 and αCD28 antibodies, followed by IL-10 cytokine secretion assay to allow sorting of IL-10^+^ cells. This strategy minimized the manipulation of cells *in vitro* but still allowed us to obtain a sufficient number of CD4^+^IL-10^+^ T cells for analysis (3--5% of total CD4^+^ T cells). The phenotype of highly purified IL-10^+^ cells differed significantly from the IL-10^−^ subpopulation. TIM-3 expression was significantly higher on IL-10^+^ T cells as compared to the IL-10^−^ subset (*p* = 0.0008) and was present in approximately 25% of CD4^+^ T cells, while 80% of CD4^+^IL-10^+^ T cells expressed PD-1 (*p* = 0.007), which was significantly higher when compared to the IL-10^−^ fraction. Within the PD-1^+^ T cell population, the percentages of CD49b^+^ and LAG-3^+^ cells were lower, both below 10% and although higher than the IL-10^+^ subset, the differences were not statistically significant (Figure [2](#F2){ref-type="fig"}A).

![**(A)** The expression of IRs on purified CD4^+^IL-10^+^/IL-10^−^ T cells. Magnetically sorted CD4^+^ T cells were cultured for 16 h in the presence of 1 μg/ml αCD3 and 2 μg/ml of αCD28 antibodies, then harvested, subjected to IL-10 cytokine secretion assay, and sorted by flow cytometry according to their IL-10 expression. Graphs represent the percentages of IL-10^+^ or IL-10^−^ T cells, expressing each IR determined by flow cytometry (*n* = 4). Purified CD4^+^IL-10^+/−^ T cells were rested for 48 h in the presence of 60 U/ml IL-2 and then were restimulated for 4 h with αCD3 and αCD28 antibodies. **(B)** mRNA levels of IRs on sorted CD4^+^IL-10^+/−^ T cells. Purified CD4^+^IL-10^+/−^ T cells were rested for 48 h in the presence of 60 U/ml IL-2 and then were restimulated for 4 h with αCD3 and αCD28 antibodies. Graphs show mean gene expression levels as relative values compared to HPRT-1 (*n* = 4). **(C)** Expression of IRs on CD4^+^IL-10^+/−^ T cell fraction at the point of RNA isolation as evaluated by flow cytometry. Figure shows percentages of viable CD4^+^IL-10^+/−^ T cells expressing the indicated marker (mean + SEM, *n* = 4). The significance has been analyzed using *t* test.](fimmu-07-00355-g002){#F2}

To correlate the surface phenotype with RNA levels, we performed RT-PCR on restimulated IL-10^+^ and IL-10^−^ cells, which were previously rested for 48 h in the presence of human recombinant IL-2. RT-PCR analysis demonstrated a significant increase in TIGIT expression among IL-10^+^ T cells (*p* = 0.03) and a trend toward higher levels of TIM-3 mRNA levels among IL-10^+^ T cells as compared to the IL-10^−^ T cell subset (Figure [2](#F2){ref-type="fig"}B), pointing to these two markers as preferential for Tr1-like T cells. However, our flow cytometry analysis of surface IR levels performed at the same time point resulted in a different pattern of expression. There were no statistically significant differences in TIM-3 expression between IL-10^+^ and IL-10^−^ T cells (approximately 10%), similar to LAG-3^+^ (5%), much lower as compared to relative RNA levels. By contrast, TIGIT^+^IL-10^+^ T cells comprised 25% and PD-1^+^ 50% of IL-10^+^ T cells, while their RNA levels were lower than those of TIM-3 and LAG-3. It is also important to note that there were no noticeable differences in the percentages of TIM-3, TIGIT, and PD-1 between IL-10^+^ and IL-10^−^ T cell subsets at this time point (Figure [2](#F2){ref-type="fig"}C). This result could be explained by the fact that these IRs are stored intracellularly ([@B49]--[@B51]) and released to the surface with different kinetics; so although their mRNA is upregulated, this may contribute to intracellular pools rather than cell surface expression of the markers. It has been previously shown that large pools of LAG-3 are stored intracellularly ([@B49]), and we were able to detect large proportions of intracellular LAG-3 in both IL-10^+^ and IL-10^−^ T cells (data not shown). It is possible that the kinetics of LAG-3 release to the cell surface correlates with the suppressive phenotype of the cells. In the same way, surface expression of TIM-3, known to reside in the Golgi apparatus and endoplasmic reticulum ([@B50]), could be differentially regulated on the IL-10^+^ as compared to the CD4^+^IL-10^−^ subpopulation. There is also evidence for altered regulation of TIM-3 expression in acute myeloid leukemia, where the majority of TIM-3 is expressed on the surface of PMBC as compared to healthy individuals, where TIM-3 is mainly detected intracellularly ([@B51]).

Beyond IRs {#S3}
==========

Due to the lack of any firm evidence demonstrating an exclusive IR marker for Tr1-like T cells, emerging evidence points toward new molecules that might serve as their biomarkers. In 2015, Blumberg's group published a very elegant study in which they demonstrated that surface expression of TIM-3 is regulated by carcinoembryonic antigen cell adhesion molecule 1 (CEACAM-1), which has the ability to form a heterodimer with TIM-3 in human and murine CD4^+^ T cells ([@B50]). Furthermore, lower proportions of tumor-infiltrating murine CD4^+^ and CD8^+^ T cells produced IL-10 after co-blockade of CEACAM-1 and TIM-3 *in vivo* ([@B50]). Equally, one could speculate that CEACAM-1 could also regulate surface expression of TIM-3 on Tr1-like T cells; however, the CEACAM-1 expression on Tr1-like T cells has not yet been studied. It is known that this molecule is expressed on a small population of resting CD4^+^ T cells in humans and mice ([@B52]); hence, it could be a potential candidate for a biomarker for Tr1-like T cells.

The second putative candidate is Granzyme B. Previous studies have shown that human and murine CD4^+^ T cells, which acquire a Tr-1-like phenotype, express Granzyme B ([@B53]--[@B55]). A recent publication by Schmetterer et al. demonstrates that human CD4^+^ T cells transduced with the active form of STAT3 produce higher levels of IL-10 and Granzyme B, which was responsible for the suppressive activity of these cells ([@B56]). It is worthwhile to point out that the cells did not display elevated levels of CD49b and LAG-3 ([@B56]). Interestingly, blocking CEACAM1 increased the cytolytic function of human CD8^+^ T cells ([@B52]); hence, this molecule if expressed on CD4^+^IL-10^+^ T cells could influence their cytotoxic function by regulating Granzyme B expression.

The third possible candidate to serve as a marker for Tr1-like T cells is class I-restricted T cell-associated molecule (CRTAM) expressed on both CD4^+^ and CD8^+^ T cells upon activation. This molecule was upregulated on Tr1-like T cells as a result of tolerance induction after administration of escalating doses of MBP peptide ([@B7]). Recently, Saito's group demonstrated that CRTAM is expressed on a specific subset of CD4^+^ T cells, which are characterized by high production of IFNγ, expression of Granzyme B, and Eomes after TCR activation, and can develop cytotoxic properties in both mice and humans ([@B57]). A comparison of the phenotype of CD4^+^CRTAM^+^ T cells with Tr1-like T cells in relation to expression of Granzyme B and CEACAM-1 would provide an insight into the functional differences within a heterogeneous subset of human Tr1-like T cells, especially given that, according to our observations, 50% of these cells expressed IFNγ.

In summary, our phenotypic analyses suggest that none of the analyzed IRs can be described as surrogate markers for Tr1-like T cells. Ideally, such a biomarker would be a stable, constitutively expressed cell surface molecule, easily detected on freshly isolated human CD4^+^ T cells. In the quest to identify it, more detailed analyses using RNA profiling and unbiased proteomics together with studies of epigenetic changes at the IL-10 promoter should be performed. Our laboratory analyzed changes in histone H3 modification at the IL-10 promoter and found similar epigenetic changes in mouse and human CD4^+^IL-10^+^ T cells ([@B58]). However, Dong et al. found limited epigenetic changes in the status of human IL-10 promoter and a lack of functional memory for IL-10 re-expression in cultured IL-10 secreting cells ([@B59]). It is clear that all T cell subsets can secrete IL-10 under certain circumstances ([@B3]). Therefore, the question as to whether Tr1 cells constitute a distinct lineage remains open and requires further investigation.
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